Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its Adc Payload Technology
Stockholm, Sweden, March 06, 2023 (GLOBE NEWSWIRE) -- Simris Alg AB (publ), a European biologics company focused on extracting high value biological active compounds from microalgae and cyanobacteria, today announced a framework collaboration agreement with Lonza Ltd, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, to commercialize Simris’ ADC payload platform.
- With more than 210 novel ADC clinical trials started in 2022, the market for ADC medicines continues to develop in line with their recognition as effective, stable and reliable cancer therapeutics.
- Under the terms of the agreement, Lonza will integrate Simris’ ADC payload technology into the Lonza Bioconjugation Toolbox and will gain the exclusive right to offer the technology to new and existing customers seeking novel payloads to develop into ADC medicines.
- In return, Simris will promote Lonza to customers as its exclusive contract drug and manufacturing organization (CDMO) partner for services using its ADC technology.
- Julian Read, CEO at Simris Alg AB, commented, “We are delighted that Lonza shares our confidence in the potential of our ADC payload technology.